Refine Search

Search Results -

Term	Documents
TRANSDERMAL	40464
TRANSDERMALS	16
NEEDLESS	58620
NEEDLESSES	0
(11 AND (NEEDLESS OR TRANSDERMAL)).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	0
(L11 AND (TRANSDERMAL OR NEEDLESS)).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	0

Database:
US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L12

Refine Search | Recall Text | Clear | Interrupt

Search History

DATE: Wednesday, December 29, 2004 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES; OP=AND			
L12	L11 and (transdermal or needless)	0	L12
L11	L10 not L8	25	L11
L10	L3 and (densified adj particle)	26	L10
L9	L7 not L8	4	L9
L8	L7 and (protein or peptide or drug)	52	L8

L7	L6 or L5	56	L7
L6	L4 not L5	45	L6
L5	L3 and (needleless)	11	L5
L4	L3 and (transdermal adj delivery)	53	L4
L3	L2 and (mill or sieve or (size adj reducing))	20931	L3
L2	(compacting or compaction or pressing or press) same (particulate or granulate or particle or granule)	88700	L2
L1	Burkoth-Terry-Lee.in.	5	L1

END OF SEARCH HISTORY

Refine Search

Search Results -

Term	Documents
(12 NOT 6).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	32
(L12 NOT L6).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	32

Database: US Pre-Grant Publication Full-Text Database; US Patents Full-Text Database; US OCR Full-Text Database; EPO Abstracts Database; JPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L13

Refine Search | Recall Text | Clear | Interrupt

Search History

DATE: Thursday, December 30, 2004 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES; OP=AND			
L13	L12 not L6	32	L13
L12	L10 and (needleless or transdermal or (particle adj delivery))	32	L12
L11	L10 and (densified)	2	L11
L10	L9 and (mill or sieve or milling or sieving)	263	L10
L9	L7 and (compact or compacting or pressing or rolling)	826	L9
L8	L7 and (powder adj production)	23	L8
L7	(Insulin or testosterone or (therapeutic adj agent) or antibiotic or cephalexin) same (powder or powdered)	10203	L7
L6	L1 same (compact or press or compacting or pressing or rolling)	101	L6
L5	L2 not L4	15	L5
L4	L2 and (compact or press or compacting or pressing or rolling)	13	L4

L3	L2 same (compact or press or compacting or pressing or rolling)	0	L3
L2	((powdered adj therapeutic) adj agent)	28	L2
L1	(insulin) same (powder)	1434	L1

END OF SEARCH HISTORY

PALM INTRANET

Day : Wednesday
Date: 12/29/2004
Time: 11:13:05

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name	First Name	
Burkoth	Terry Lee	Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

PALM INTRANET

Day : Wednesday
Date: 12/29/2004
Time: 11:13:05

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name	First Name	
Sarphie	David	Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

```
                          Welcome to DialogClassic Web(tm)
 Dialog level 04.20.00D
Last logoff:  27dec04 13:43:59
Logon file001 29dec04 17:04:12
          *** ANNOUNCEMENT ***
                     ***
--Important Notice to Freelance Authors--
See HELP FREELANCE for more information
                     ***
NEW FILES RELEASED
***German Patents Fulltext (File 324)

***Beilstein Abstracts (File 393)
***Beilstein Facts (File 390)
***Beilstein Reactions (File 391)
                     ***
UPDATING RESUMED
                     ***
                     ***

     >>> Enter BEGIN HOMEBASE for Dialog Announcements <<<
     >>>    of new databases, price changes, etc.      <<<
                     ****
KWIC is set to 50.
HILIGHT set on as ' '
 * * *
File   1:ERIC 1966-2004/Jul 21
       (c) format only 2004 The Dialog Corporation

      Set  Items  Description
      ---  -----  -----------
Cost is in DialUnits
?
B 155, 5, 73
       29dec04 17:04:34 User259876 Session D699.1
            $0.80    0.228 DialUnits File1
     $0.80  Estimated cost File1
     $0.09  INTERNET
     $0.89  Estimated cost this search
     $0.89  Estimated total session cost   0.228 DialUnits

SYSTEM:OS  - DIALOG OneSearch
  File 155:MEDLINE(R) 1951-2004/Dec W1
        (c) format only 2004 The Dialog Corp.
 *File 155: Medline has stopped updating as of December 7, 2004.
Please see HELP NEWS 155 for details.
  File   5:Biosis Previews(R) 1969-2004/Dec W3
        (c) 2004 BIOSIS
  File  73:EMBASE 1974-2004/Dec W3
        (c) 2004 Elsevier Science B.V.

      Set  Items  Description
      ---  -----  -----------
?
S (COMPACTING OR COMPACTION OR PRESSING OR PRESS) (S) (PARTICULATE OR GRANULATE OR P
            699  COMPACTING
          10142  COMPACTION
          13475  PRESSING
         231516  PRESS
          73994  PARTICULATE
            751  GRANULATE
         239372  PARTICLES
         118191  GRANULES
      S1   1961  (COMPACTING OR COMPACTION OR PRESSING OR PRESS) (S)
                 (PARTICULATE OR GRANULATE OR PARTICLES OR GRANULES)
```

```
?
?
S S1 AND (MILL OR SIEVE OR (SIZE (W) REDUCING))
            1961  S1
           22909  MILL
            9420  SIEVE
         1007207  SIZE
          320535  REDUCING
             134  SIZE(W)REDUCING
      S2      25  S1 AND (MILL OR SIEVE OR (SIZE (W) REDUCING))
?
S S2 AND (TRANSDERMAL OR NEEDLELESS)
              25  S2
           22410  TRANSDERMAL
             540  NEEDLELESS
      S3       0  S2 AND (TRANSDERMAL OR NEEDLELESS)
?

Set     Items   Description
S1       1961   (COMPACTING OR COMPACTION OR PRESSING OR PRESS) (S) (PARTI-
           CULATE OR GRANULATE OR PARTICLES OR GRANULES)
S2         25   S1 AND (MILL OR SIEVE OR (SIZE (W) REDUCING))
S3          0   S2 AND (TRANSDERMAL OR NEEDLELESS)
?
S S2 NOT PY>1996
              25  S2
        11779291  PY>1996
      S4      10  S2 NOT PY>1996
?
RD
...completed examining records
      S5       6  RD (unique items)
?
T S5/3,K/ALL

  5/3,K/1     (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.

08231327   PMID: 2760828
 Preliminary  studies of the development of a direct compression cellulose
 excipient from bagasse.
  Padmadisastra Y; Gonda I
  Department of Pharmacy, University of Sydney, NSW, Australia.
  Journal  of  pharmaceutical sciences (UNITED STATES)   Jun 1989,  78  (6)
 p508-14,  ISSN 0022-3549   Journal Code: 2985195R
  Document type: Journal Article
  Languages: ENGLISH
  Main Citation Owner: NLM
  Record type: Completed

  ... improve  the  disintegration  properties  of  tablets  made from this
```

material, DICEB III. When the bagasse-derived cellulose was reconstituted by recombining different proportions of selected **sieve** cuts to have a similar **sieve** size distribution as the commercially available MCC, Avicel PH102, it was found that the latter and DICEB III also had similar crystallinity as measured by...

... hardness (11.6 +/- 1.1 and 13.7 +/- 0.5 kPa, respectively). They displayed similar satisfactory disintegration and dissolution behavior. However, DICEB III required greater **compaction** pressures than Avicel PH102, perhaps because the former was not spray dried to give spherical agglomerates of **particles** of uniform size as the commercial product. Rather, DICEB III consisted mainly of single irregular **particles** . Further work is required to improve the new excipient and to explore if the bagasse from mechanically harvested sugar cane (often contaminated by soil) could ...

5/3,K/2 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

07142004 PMID: 3714438
Studies on tableting properties of lactose. Part III. The consolidation behaviour of sieve fractions of crystalline alpha-lactose monohydrate.
De Boer A H; Vromans H; Lerk C F; Bolhuis G K; Kussendrager K D; Bosch H
Pharmaceutisch weekblad. Scientific edition (NETHERLANDS) Apr 25 1986, 8 (2) p145-50, ISSN 0167-6555 Journal Code: 7907992
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

Studies on tableting properties of lactose. Part III. The consolidation behaviour of sieve fractions of crystalline alpha-lactose monohydrate.
The consolidation and **compaction** behaviour of **sieve** fractions of crystalline alpha-lactose monohydrate were studied. From mercury porosimetry measurements tablet pore surface areas were derived. At a certain **compaction** load it appeared that tablets compressed from small **particles** were generally stronger and showed a larger surface area than compacts prepared from coarse **sieve** fractions. By plotting compact strength against pore surface area, a unique linear relationship was obtained. From these results it can be concluded that the actual tablet surface area, being a function of both the initial particle size and applied **compaction** pressure, is responsible for the compact strength.

5/3,K/3 (Item 3 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

04069066 PMID: 1151631
Effect of compaction on particle size.
Khan K A; Rhodes C T
Journal of pharmaceutical sciences (UNITED STATES) Mar 1975, 64 (3) p444-7, ISSN 0022-3549 Journal Code: 2985195R
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

Compressed tablets were prepared on a hydraulic **press** at several different **compaction** pressures by a standardized technique, using aspirin, dicalcium phosphate dihydrate, calcium phosphato-carbonate, alumina, and microcrystalline cellulose. All tablets except microcrystalline cellulose contained a cation-exchange resin as

disintegrant. The particle-size spectra of the disintegrating compacts were evaluated using a particle-size counter or an air jet **sieve** . It is shown that compacts made from different materials but of the same initial particle-size spectra disintegrate to give **particles** of a considerably different size. Determination of the change in particle size produced by the **compaction** process provides useful insight into the nature of the **compaction** process.

5/3,K/4 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0008201643 BIOSIS NO.: 199293044534
CONSOLIDATION AND COMPACTION OF POWDER MIXTURES II. BINARY MIXTURES OF DIFFERENT PARTICLE SIZE FRACTIONS OF ALPHA LACTOSE MONOHYDRATE
AUTHOR: RIEPMA K A (Reprint); VEENSTRA J; DE BOER A H; BOLHUIS G K; ZUURMAN K; LERK C F; VROMANS H
AUTHOR ADDRESS: DEP PHARMACEUTICAL TECHNOLOGY BIOPHARMACY, UNIVERSITY GRONINGEN, ANT DEUSINGLAAN 1, 9713 AV GRONINGEN, THE NETHERLANDS** NETHERLANDS
JOURNAL: International Journal of Pharmaceutics (Kidlington) 76 (1-2): p 9-16 1991
ISSN: 0378-5173
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

...ABSTRACT: powder fractions. The extent of decreased strength and decreased surface area of the tablets was found to depend upon the weight ratio of the finer **sieve** fraction in the blend and to increase with the diameter ratio between coarse and finer **particles** . These results indicate an interaction with respect to consolidation and **compaction** which is explained by decreased fragmentation potentials, caused by increased packing densities of the binary mixtures of different particle size fractions of crystalline lactose. All...

5/3,K/5 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0001933129 BIOSIS NO.: 197662029268
INFLUENCE OF THE PHYSICAL FORM OF DEHYDRATED FORAGES ON SHEEP RUMEN FERMENTATIONS COMPARISON BETWEEN LEGUMES AND GRASSES
AUTHOR: MASSON C; CANDAU M; TISSERAND J-L
JOURNAL: Annales de Zootechnie (Paris) 24 (2): p199-208 1975
ISSN: 0003-424X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: Unspecified

...ABSTRACT: physical form of dehydrated forages, 3 grasses and 2 legumes, on ruminal fermentation. The forages were either chopped (normal form), wafered (agglomerated in a wafering **press**) or cobbed (agglomerated without previous grinding in an 8 mm pellett **mill**). The mean size of the forage **particles** varied from 0.45-4.05 mm according to the treatment. The physical form of the forages significantly affected feed intake level and only slightly...

5/3,K/6 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

02789474 EMBASE No: 1984008433
Bioprotein production from the waste products of olive oil extraction
Karapinar M.; Worgan J.T.
Natl. Coll. Food Technol., Univ. Reading, Weybridge, Surrey United Kingdom
Journal of Chemical Technology and Biotechnology (J. CHEM. TECHNOL. BIOTECHNOL.) (United Kingdom) 1983, 33 B/3 (185-188)
CODEN: JCTBD
DOCUMENT TYPE: Journal
LANGUAGE: ENGLISH

After the expression of the oil from olive fruits, two principal residues, namely the **press** -cake and the vegetable water (black liquor), remain. These by-products of olive processing have little economic significance, despite studies carried out to evaluate them. In this study, growth of Aspergillus oryzae, Aspergillus niger, Sporotrichum pulverulentum and Trichoderma viride on the solid waste was examined in shake flasks. The **press** -cake contains a proportion of tissue which is resistant to microbial attack. Microbial growth on the original solid waste was poor and did not decrease the cellulose content appreciably, even after alkali treatment. Therefore the **press** -cake was milled in a hammer **mill** and larger **particles** were separated by sieving. The protein content of the product was about 19-24%, and about 52% of the cellulose present in the sieved residue...
?

```
Set     Items   Description
S1       1961   (COMPACTING OR COMPACTION OR PRESSING OR PRESS) (S) (PARTI-
            CULATE OR GRANULATE OR PARTICLES OR GRANULES)
S2         25   S1 AND (MILL OR SIEVE OR (SIZE (W) REDUCING))
S3          0   S2 AND (TRANSDERMAL OR NEEDLELESS)
S4         10   S2 NOT PY>1996
S5          6   RD (unique items)
?
S (DENSIFIED (W) PARTICLE?) AND (TRANSDERMAL OR NEEDLELESS)
             192  DENSIFIED
          338476  PARTICLE?
               4  DENSIFIED(W)PARTICLE?
           22410  TRANSDERMAL
             540  NEEDLELESS
      S6       0  (DENSIFIED (W) PARTICLE?) AND (TRANSDERMAL OR NEEDLELESS)
?
S (NEEDLELESS OR TRANSDERMAL)
             540  NEEDLELESS
           22410  TRANSDERMAL
      S7   22947  (NEEDLELESS OR TRANSDERMAL)
?
S S7 AND (COMPACTING OR PRESSING)
           22947  S7
             699  COMPACTING
           13475  PRESSING
      S8       5  S7 AND (COMPACTING OR PRESSING)
?
RD
...completed examining records
      S9       5  RD (unique items)
?
T S9/3,K/ALL
```

9/3,K/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0014677905 BIOSIS NO.: 200400058662
Method and delivery device for the transdermal **administration of a**

substance
AUTHOR: Gertsek Marina (Reprint); Wilkinson Bradley M; Pettis Ronald J
AUTHOR ADDRESS: Ridgewood, NJ, USA**USA
JOURNAL: Official Gazette of the United States Patent and Trademark Office Patents 1277 (1): Dec. 2, 2003 2003
MEDIUM: e-file
PATENT NUMBER: US 6656147 PATENT DATE GRANTED: December 02, 2003 20031202
PATENT CLASSIFICATION: 604-28 PATENT ASSIGNEE: Becton, Dickinson and Company PATENT COUNTRY: USA
ISSN: 0098-1133 _(ISSN print)
DOCUMENT TYPE: Patent
RECORD TYPE: Abstract
LANGUAGE: English

Method and delivery device for the transdermal **administration of a substance**

...ABSTRACT: cover member enclosing a bladder containing the substance to be delivered. The bottom wall of the housing has at least one cannula facing the bladder. **Pressing** on the top cover member causes the cannula to puncture the bladder and deliver the substance to the microneedles for delivery to the patient. In...
DESCRIPTORS:
METHODS & EQUIPMENT: **transdermal** substance administration delivery device...

... **transdermal** substance administration delivery method

9/3,K/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0013076294 BIOSIS NO.: 200100248133
Medical adapter having needleless **valve and sharpened cannula**
AUTHOR: Leinsing Karl R (Reprint)
AUTHOR ADDRESS: Raleigh, NC, USA**USA
JOURNAL: Official Gazette of the United States Patent and Trademark Office Patents 1240 (1): Nov. 7, 2000 2000
MEDIUM: e-file
PATENT NUMBER: US 6142446 PATENT DATE GRANTED: November 07, 2000 20001107
PATENT CLASSIFICATION: 251-1491 PATENT ASSIGNEE: Alaris Medical Systems, Inc., San Diego, CA, USA PATENT COUNTRY: USA
ISSN: 0098-1133
DOCUMENT TYPE: Patent
RECORD TYPE: Abstract
LANGUAGE: English

Medical adapter having needleless **valve and sharpened cannula**

ABSTRACT: A medical adapter having both a **needleless** valve and a sharpened cannula is used to connect or adapt pierceable septa containers or other devices having different sizes to **needleless** connection. The adapter includes a **needleless** site at one end and a sharpened cannula at the other end protected by spring arms. These arms include claws at their distal ends to...

...against the spring forces during engagement of the adapter with the septum. In one case, the handles include finger grips located above the springs for **pressing** the handles inward to open the arms and claws and in another case, the handles are located closer to the distal ends of the arms...
DESCRIPTORS:
...METHODS & EQUIPMENT: medical equipment, **needleless** valve, sharpened cannula

9/3,K/3 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

12436449 EMBASE No: 2004029452
New developments in levodopa therapy
LeWitt P.A.; Nyholm D.; Olanow; Hauser; Obeso; Stocchi; Jenner
Dr. P.A. LeWitt, Clinical Neuroscience Center, 26400 West Twelve Mile Road, Southfield, MI 48034 United States
Neurology (NEUROLOGY) (United States) 13 JAN 2004, 62/1 SUPPL. 1 (S9-S16)
CODEN: NEURA ISSN: 0028-3878
DOCUMENT TYPE: Journal ; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 46

...dopaminergic neurons, but this has since been answered by in vivo studies finding no evidence of toxicity and possibly even neurotrophic-like effects. A more **pressing** concern regarding levodopa is its association with the development of motor complications after long-term use. Pulsatile dopaminergic stimulation as a result of erratic absorption...
DRUG DESCRIPTORS:
...*therapy--dt; *levodopa--drug toxicity--to; *levodopa--pharmacokinetics --pk; *levodopa--intraduodenal drug administration--du; *levodopa --intravenous drug administration--iv; *levodopa--oral drug administration --po; *levodopa-- **transdermal** drug administration--td

9/3,K/4 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE

05997377 EMBASE No: 1995026022
PEPI in perspective: Good answers spawn pressing **questions**
Healy B.
One Clinic Center, Cleveland Clinic Foundation, 9500 Euclid Ave,Cleveland, OH 44195-5108 United States
Journal of the American Medical Association (J. AM. MED. ASSOC.) (United States) 1995, 273/3 (240-241)
CODEN: JAMAA ISSN: 0098-7484
DOCUMENT TYPE: Journal; Editorial
LANGUAGE: ENGLISH

PEPI in perspective: Good answers spawn pressing **questions**
MEDICAL DESCRIPTORS:
clinical trial; diabetes mellitus; editorial; endometrium hyperplasia--side effect--si; estrogen therapy; female; heart protection; human; hypertension ; intramuscular drug administration; priority journal; stroke; thromboembolism; **transdermal** drug administration

9/3,K/5 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE

05070509 EMBASE No: 1992210725
Physicochemical and biologic properties of interferons and their potential uses in drug delivery systems
Bocci V.
General Physiology/Nutr. Sci. Inst., Faculty of Pharmacy, University of Siena,53100 Siena Italy
Critical Reviews in Therapeutic Drug Carrier Systems (CRIT. REV. THER. DRUG CARRIER SYST.) (United States) 1992, 9/2 (91-133)

```
  CODEN: CRTSE   ISSN: 0743-4863
  DOCUMENT TYPE: Journal; Review
  LANGUAGE: ENGLISH   SUMMARY LANGUAGE: ENGLISH

  ...IFNs are normally not circulatory proteins, and because they are
unselective during therapeutic intervention, toxicity can overcome
beneficial effects. For this reason, there is a pressing need to optimize
treatment, dosages, and schedules for improving the therapeutic index. A
further important issue is the definition of routes of IFN administration
able...
MEDICAL DESCRIPTORS:
...drug administration; intranasal drug administration; intraperitoneal
drug administration; intravaginal drug administration; intravenous drug
administration; nonhuman; rectal drug administration; review; subcutaneous
drug administration; topical drug administration; transdermal drug
administration
?

Set     Items   Description
S1       1961   (COMPACTING OR COMPACTION OR PRESSING OR PRESS) (S) (PARTI-
            CULATE OR GRANULATE OR PARTICLES OR GRANULES)
S2         25   S1 AND (MILL OR SIEVE OR (SIZE (W) REDUCING))
S3          0   S2 AND (TRANSDERMAL OR NEEDLELESS)
S4         10   S2 NOT PY>1996
S5          6   RD (unique items)
S6          0   (DENSIFIED (W) PARTICLE?) AND (TRANSDERMAL OR NEEDLELESS)
S7      22947   (NEEDLELESS OR TRANSDERMAL)
S8          5   S7 AND (COMPACTING OR PRESSING)
S9          5   RD (unique items)
?
COST
       29dec04 17:12:48 User259876 Session D699.2
            $1.90    0.593 DialUnits File155
               $0.63  3 Type(s) in Format  3
            $0.63  3 Types
     $2.53  Estimated cost File155
            $3.63    0.648 DialUnits File5
               $7.00  4 Type(s) in Format  3
            $7.00  4 Types
    $10.63  Estimated cost File5
            $5.23    0.533 DialUnits File73
              $10.80  4 Type(s) in Format  3
           $10.80  4 Types
    $16.03  Estimated cost File73
            OneSearch, 3 files,  1.774 DialUnits FileOS
     $2.25  INTERNET
    $31.44  Estimated cost this search
    $32.33  Estimated total session cost   2.002 DialUnits
?
```

Return to logon page!

Nguy n, Quang (AU1632)

T : Interference search

I am thinking of allowing:

A method for forming densified particles from a particulate pharmaceutical preparation, wherein the particulate pharmaceutical preparation is a preparation of a peptide or a protein, the method comprising compacting the preparation in a press to provide a compacted pharmaceutical composition and size-reducing the compacted preparation into densified particles of suitable size and density for transdermal delivery thereof by needleless injection.

Inventors: Burkoth et al.

EFD: 6/17/1996

I am aware of WIPO and US patents issued to Brian John Bellhouse.

Any potential interference?

Thanks.